Search

Date 2022 Author/Creator Mehta, Minal

1. Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study. (March 2022)

Authors:
Popat, Sanjay; Ramalingam, Suresh; Kim, Tae Min; Yang, James; Riely, Gregory; Mekhail, Tarek; Nguyen, Danny; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Spira, Alexander; Piotrowska, Zofia; Bazhenova, Lyudmila; Vincent, Sylvie; Jin, Shu; Griffin, Celina; Diderichsen, Paul; Gupta, Neeraj; Bun...
Journal:
Lung cancer
Issue:
Volume 165(2022)Supplement 1
Page Start:
S30
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study. Issue 2 (29th May 2022)

Authors:
Gupta, Neeraj; Largajolli, Anna; Witjes, Han; Diderichsen, Paul M.; Zhang, Steven; Hanley, Michael J.; Lin, Jianchang; Mehta, Minal
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 112:Issue 2(2022)
Page Start:
327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search